Tarek H Mouhieddine

24PUBLICATIONS
173CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Apr 08, 2026
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.

Omar Nadeem, Michelle P Aranha, Robert A Redd

|Mar 30, 2026
Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma.

Darren Pan, Tarek H Mouhieddine, Tianxiang Sheng

|Nov 05, 2025
Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.

Junia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman

|Aug 20, 2025
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy.

Adolfo Aleman, Oliver Van Oekelen, David T Melnekoff

|May 03, 2025
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma.

Darren Pan, Tarek H Mouhieddine, Tianxiang Sheng

|Feb 26, 2025
Impact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis.

Bruno Almeida Costa, Danai Dima, Tomer Mark

Pageof 4

Frequent Collaborators

7 joint publications

Irene M Ghobrial

7 joint publications

Hearn Jay Cho

6 joint publications

Gad Getz

6 joint publications

Joshua Richter